CLSN Celsion Corporation

0.30
+0  (11%)
Previous Close 0.27
Open 0.28
Price To book 0.67
Market Cap 7.82M
Shares 26,078,000
Volume 2,897,123
Short Ratio 0.18
Av. Daily Volume 2,688,380

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 17701879
  2. 8-K - Current report 17692999
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 17625630
  4. 424B4 - Prospectus (Rule 424(b)(4)) 17616255
  5. 8-K - Current report 17612861

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Failed to meet primary endpoint. New Phase 3 trial initiated, with enrollment to be completed early 2018 with first interim efficacy endpoint due 4Q 2018.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1b interim data released January 17, 2016 with final data due 2Q 2017.
GEN-1 OVATION
Ovarian cancer

Latest News

  1. CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  2. Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update
  3. Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
  4. Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017
  5. Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
  6. Celsion Corp. Cancer Medications Insider Buying and Analysis
  7. CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. Celsion Corporation Announces $5.0 Million Public Offering
  9. CELSION CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  10. ETFs with exposure to Celsion Corp. : January 19, 2017
  11. Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
  12. Celsion Corporation Announces Issuance of Two New Patents for ThermoDox®
  13. Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
  14. CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
  15. ETFs with exposure to Celsion Corp. : December 22, 2016
  16. CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  17. CELSION CORP Financials
  18. ETFs with exposure to Celsion Corp. : November 16, 2016
  19. Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
  20. CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits